Taysha Gene Therapies, Inc.
TSHA
$1.24
$0.065.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -43.90% | -62.33% | -53.57% | -27.52% | 44.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.90% | -62.33% | -53.57% | -27.52% | 44.04% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -43.90% | -62.33% | -53.57% | -27.52% | 44.04% |
| SG&A Expenses | 3.20% | -7.78% | 18.33% | -19.05% | -46.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.16% | 12.11% | -13.06% | 30.45% | -3.23% |
| Operating Income | -26.18% | -34.71% | 8.92% | -46.93% | 9.97% |
| Income Before Tax | -139.35% | 78.20% | 14.92% | -36.54% | 186.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.35% | 78.20% | 14.92% | -36.54% | 186.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.35% | 78.20% | 14.92% | -36.54% | 186.68% |
| EBIT | -26.18% | -34.71% | 8.92% | -46.93% | 9.97% |
| EBITDA | -27.20% | -35.70% | 8.96% | -47.92% | 10.20% |
| EPS Basic | -130.88% | 89.77% | 76.52% | 62.67% | 123.21% |
| Normalized Basic EPS | -129.69% | 91.66% | 77.98% | 62.67% | 171.18% |
| EPS Diluted | -130.88% | 89.77% | 76.52% | 62.67% | 123.21% |
| Normalized Diluted EPS | -129.69% | 91.66% | 77.98% | 62.67% | 171.18% |
| Average Basic Shares Outstanding | 27.44% | 113.06% | 262.40% | 265.55% | 273.48% |
| Average Diluted Shares Outstanding | 27.44% | 113.06% | 262.40% | 265.55% | 273.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |